Latest bacterial pneumonia Stories
Bacterial pneumonia is one of the commonest and most serious infections occurring in people infected with HIV. A metanalysis of cohort and case control studies published in BioMed Central's open access journal BMC Medicine finds that current smokers with HIV were at double the risk of bacterial pneumonia than non-smoking counterparts, but that when people stopped smoking their risk was reduced. The metanalysis reanalysed the data of several thousand participants with HIV, from 14 studies...
Connie K. Ho for redOrbit.com – Your Universe Online Scientists recently revealed that they plan to study the pneumococcal vaccines in older adults to determine if there’s a strong immune response due to a higher dosage of the vaccine. The study, funded by the National Institute of Health (NIH) as well as the National Institute of Allergy and Infectious Diseases, looked at a group of adults who previously received a vaccine that worked against pneumonia and other pneumococcal diseases....
Immunization, including flu vaccine, can thwart pneumonia in children, guidelines suggest Immunizations, including a yearly flu vaccine, are the best way to protect children from life-threatening pneumonia, according to new guidelines from the Pediatric Infectious Diseases Society (PIDS) and the Infectious Diseases Society of America (IDSA). The guidelines, which are the first on diagnosing and treating community-acquired pneumonia (CAP) in infants and children, place preventing...
Discovery could lead to novel ways of treating infectionA structural molecule and the cellular pump that regulates its levels influence the severity of pneumonia and could provide new ways of treating the lung infection, which is a leading cause of hospitalization and death, according to scientists at the University of Pittsburgh and the University of Iowa. Their findings are available online in Nature Medicine.Despite decades of research, there has been little new information on what...
The number of children admitted to English hospitals with bacterial pneumonia decreased by a fifth in the 2 years following the introduction of a vaccine to combat the diseaseThe number of children admitted to English hospitals with bacterial pneumonia decreased by a fifth in the two years following the introduction of a vaccine to combat the disease, according to a new study published August 27 in the journal Thorax.Bacterial pneumonia is a serious illness caused by Streptococcus pneumoniae...
CHICAGO, Aug. 24 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced plans to seek additional government funding for development of its novel, once-daily antibiotic, Restanza(TM) (cethromycin) based on a new, high-profile report from the Department of Health and...
CHICAGO, Aug. 10 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, announced today that it has reached agreement with the United States Food and Drug Administration (FDA), under the Special Protocol Assessment (SPA) process, on the design of its planned Phase 3 study of its...
CHICAGO, June 30 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company developing Restanza(TM), a novel once-a-day oral antibiotic, today announced that it has submitted a final Special Protocol Assessment (SPA) with the FDA for the proposed Phase III clinical program of Restanza in the treatment of patients with community acquired bacterial pneumonia (CABP). The Company has been engaged in the SPA process with the FDA over...
CHICAGO, March 11 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, announced today that the U.S. Food and Drug Administration (FDA) has provided guidance on the clinical program required to assess the approvability of Restanza(TM) (cethromycin), a novel oral once-a-day...
CHICAGO, March 11 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced its financial results for the fourth quarter and full year ended December 31, 2009. (Logo: http://www.newscom.com/cgi-bin/prnh/20080218/ALSLOGO) The net loss allocable to common shareholders...
